Privately-held German drug major Boehringer Ingelheim says that it has made more than $350 million worth of capital investments throughout its US operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities. Family-owned Boehringer Ingelheim says it continues to grow by improving its state-of-the-art facilities and enhancing its research, development and manufacturing capabilities.
The latest investment is a 72,000 square-foot R&D facility at the company's US headquarters in Ridgefield, Connecticut. When complete the $65 million facility will handle production of active pharmaceutical ingredients used in early development activities. Products developed here, if approved, move on to Boehringer Ingelheim's full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.
Other US investment in 2011
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze